ClinicalTrials.gg
Not yet recruitingNCT07690826Updated Jul 8, 2026

A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity

A Phase 2 interventional study of HRS-4729 Injection and HRS-4729 Injection in Overweight or Obesity, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd. — 8 open to participants now, 13 under way, 4 of them phase 3. Obesity · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
6th of 24
252 · median 130
Started
2026
with 6 others
Phase 2
6 of 24
2 open now
Primary completion
2027-03
later than 8 of 12 live
Registered
22nd of 24
by date

Among the 24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd., this one is the 6th largest by planned enrollment, is one of 7 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 8 of the 12 other live ones, and was the 22nd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of once-weekly HRS-4729 injection in adults with obesity without diabetes. Approximately 252 participants will be enrolled. The primary endpoint is percent change in body weight from baseline at Week 32 versus placebo.

03

Conditions studied

  • Overweight or Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's planned enrollment of 252 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Fujian Shengdi Pharmaceutical Co., Ltd. is the lead sponsor of 66 studies on the registry; 24 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written .
  2. Male or female adults aged 18 to 65 years.
  3. : 28.0 to 40.0 kg/m2.
  4. Self-reported diet and exercise control for at least 3 months before screening, with body weight change of no more than 5 kg during the previous 3 months.

Exclusion criteria

Exclusion Criteria:

  1. Endocrine disease or history that may have a significant effect on body weight;
  2. History of diabetes mellitus (gestational diabetes excepted);
  3. of any organ system within the past 5 years, irrespective of evidence of local recurrence or , except for adequately treated localized basal cell carcinoma of the skin, carcinoma in situ of the cervix, and prostate carcinoma in situ;
  4. Presence or suspicion of depression, anxiety disorder, bipolar disorder, suicidal ideation, schizophrenia, or other psychiatric disorder, or a history of suicide attempt;
  5. Known or suspected excessive alcohol use, or a history of alcohol, drug, or substance abuse;
  6. Acute or chronic hepatitis, or a history of severe hepatic disease other than metabolic dysfunction-associated fatty liver disease;
  7. Prior or planned organ or bone marrow transplantation during the study period;
  8. Any hematologic disorder that may interfere with the determination of ;
  9. An disease for which systemic or therapy is planned during the study period;
  10. Use of any medication or treatment likely to cause clinically significant weight gain or weight loss within 3 months prior to screening;
  11. Participation in any clinical trial of an drug or medical device within 3 months prior to screening;
  12. Blood donation or blood loss ≥400 mL, or receipt of a blood transfusion, within 3 months prior to screening;
  13. Mental incapacity or language impairment sufficient to preclude adequate understanding of, or participation in, the trial procedures;
  14. Investigators, site staff, or other personnel directly involved in conduct of the study, and their immediate family members; employees of the Sponsor;
  15. Any condition that, in the investigator's judgment, would compromise participant safety or otherwise interfere with the assessment of study results.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
252 participants (estimated)

Study arms

  • Experimental
    Dose 1

    Drug: HRS-4729 Injection

    Drug: HRS-4729 Injection

  • Experimental
    Dose 2

    Drug: HRS-4729 Injection

    Drug: HRS-4729 Injection

  • Experimental
    Dose 3

    Drug: HRS-4729 Injection

    Drug: HRS-4729 Injection

  • Experimental
    Dose 4

    Drug: HRS-4729 Injection

    Drug: HRS-4729 Injection;

  • Experimental
    Dose 5

    Drug: HRS-4729 Injection

    Drug: HRS-4729 Injection;

  • Experimental
    Dose 6

    Drug: HRS-4729 Injection

    Drug: HRS-4729 Injection;

  • Placebo comparator
    Placebo

    Drug: HRS-4729 Injection Placebo

    Drug: HRS-4729 Injection Placebo

Interventions

07

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Body Weight

    Time frame: Baseline, Week 32

Secondary outcomes

  1. Percent Change From Baseline in Body Weight

    Time frame: Baseline, Week 40

  2. Change From Baseline in Body Weight

    Time frame: Baseline, Week 32 and 40

  3. Change from Baseline in Body Mass Index (BMI)

    Time frame: Baseline, Week 32 and 40

  4. Change from Baseline in Waist Circumference

    Time frame: Baseline, Week 32 and 40

  5. Change from Baseline in Blood Pressure

    Time frame: Baseline, Week 32 and 40

  6. Change from Baseline in Glucose Level

    Time frame: Baseline, Week 32 and 40

  7. TEAEs

    Time frame: Baseline, Week 44

08

Study locations

1 site
  • Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200025, China
    • Weiqing Wang · Principal investigator
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Mar 2027, 8 months later.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 8 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2026
First posted
Jul 8, 2026
StartEst.
Jul 2026
Primary completionEst.
Mar 2027
CompletionEst.
Jul 2027
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07690826
Responsible party
Sponsor
First posted
Jul 8, 2026
Start date
Jul 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jul 8, 2026

Study contacts

Ziwei Du
Contact
ziwei.du.zd9@hengrui.com
+86 0518-81220121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-4729

Start the discussion